Cebranopadol, a Novel Potent Analgesic: Binding Affinity to Opioid Receptors and In Vitro Activity (PAINWeek 2022) - Sep 19, 2022 - Abstract #23; "Cebranopadol combines μ-opioid and NOP receptor agonism in a single molecule which may contribute functionally to its safety and analgesic activity. Ongoing clinical investigations will assist in determining the role of cebranopadol in pain therapy. Objectives: Upon completion, participant will be able to describe the mechanism of action of cebranopadol."
Preclinical • CNS Disorders • Pain
|
|
David Fam, PharmD; Marc Lesnick, PhD; James Hackworth, PhD
|